Abstract
Importance Gabapentin and dihydropyridine calcium channel blockers (DHP CCBs) are commonly prescribed together in older adults: gabapentin reaches more than 15.5 million U.S. patients annually, and DHP CCBs such as amlodipine are a first-line antihypertensive class. Both classes act on neuronal calcium signaling, raising the question of whether their combined use is associated with greater cognitive risk than gabapentin alone.
Objective To examine whether concurrent CCB use, and DHP CCB use in particular, modifies the association between gabapentin initiation and incident dementia in adults with hypertension.
Design, Setting, and Participants Active-comparator new-user cohort study within the Rutgers Clinical Research Data Warehouse (2018–2024), encompassing 405 clinical sites in northern New Jersey. Participants were adults aged 40 years or older with hypertension who initiated gabapentin or pregabalin. Data were analyzed from January through December 2025.
Exposures Gabapentin vs pregabalin initiation, with pre-specified stratification by baseline CCB exposure and CCB subtype (DHP vs non-DHP).
Main Outcomes and Measures Incident dementia (ICD-10 F00–F03, G30). The pre-specified primary analysis used inverse probability of treatment weighting with time-varying CCB exposure; secondary analyses examined CCB subtype specificity, dementia subtypes, falsification outcomes, and competing risk of death.
Results Among 33,791 patients (mean [SD] age, 69.9 [11.5] years; 57.1% female; 502 dementia events; median follow-up, 1.22 years), gabapentin initiation was associated with higher dementia incidence among patients also taking a CCB than among those not taking a CCB (time-varying HR, 1.52 [95% CI, 1.23–1.89]; baseline-stratified HR, 2.22 [95% CI, 1.42–3.47]). The signal was directionally larger with DHP CCBs. Median time to dementia diagnosis was 240 days; subtype estimates were hypothesis-generating.
Conclusions and Relevance In this active-comparator cohort of older adults with hypertension, concurrent CCB use — particularly with DHP agents — was associated with substantially higher gabapentin-related dementia incidence than gabapentin without CCB exposure. The short event latency suggests the signal may partly reflect drug-induced cognitive impairment, which may improve with deprescribing — a clinically actionable possibility. CCB-subtype and dementiasubtype estimates are hypothesis-generating; confirmatory replication in Medicare fee-forservice claims and the NIH All of Us Research Program is underway.
Question In older adults with hypertension, is concurrent calcium channel blocker (CCB) use associated with higher gabapentin-related dementia incidence than gabapentin alone?
Findings In an active-comparator cohort of 33,791 adults, gabapentin initiation (vs pregabalin) was associated with higher dementia incidence among patients also taking a CCB than among those not taking a CCB (time-varying HR, 1.52 [95% CI, 1.23–1.89; P = .0003]; baselinestratified HR, 2.22 [95% CI, 1.42–3.47]; interaction P = .004). The signal was directionally larger among DHP CCB users (HR, 3.20) and concentrated in Alzheimer disease (HR, 4.53) and unspecified dementia (HR, 2.29), with a null finding for vascular dementia (HR, 0.81).
Meaning Concurrent gabapentin and DHP CCB use identifies a potentially modifiable cognitive safety signal in older adults; the short event latency raises the possibility that part of the affected cognition may be at least partially reversible after deprescribing. CCB-subtype and dementiasubtype findings are hypothesis-generating and require replication in larger cohorts; independent replication efforts in broader real-world populations are ongoing.
Competing Interest Statement
The authors have declared no competing interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used de-identified electronic health record data from the Rutgers Clinical Research Data Warehouse. The study was determined to be non-human subjects research per 45 CFR 46.102(d) through Rutgers University's Non-Human Research Self-Certification process. The study was approved by the Data Governance Council (PR0077).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
v4 corrects a single bibliographic error. Reference 52 in v3 was incorrect. The correct citation is: Thorsteinsson H, et al. Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment. Neuropsychopharmacology. 2025. doi:10.1038/s41386-025-02062-x. No other changes to content, results, or conclusions.
Data Availability
The data underlying this study cannot be shared publicly due to privacy restrictions on electronic health records. The study used de-identified data from the Rutgers Clinical Research Data Warehouse under an approved Data Use Agreement. Aggregated summary statistics are available upon reasonable request to the corresponding author.
